Alzheimer’s Biomarker Detects Disease Early
Here’s a breakdown of the key data from the provided text:
Main Finding:
Researchers at Florida International University (FIU) have discovered that levels of the translocator protein 18 kDa (TSPO) are elevated in the brains of individuals with Alzheimer’s disease, even in the early stages. This elevation is especially noticeable in microglia (brain immune cells) clustered around amyloid plaques.Key Researchers & Institution:
Dr. Guillermo Guilarte: An expert on TSPO, leading the research at FIU’s Robert Stempel College of Public Health & Social Work.
Daniel Martínez Pérez: Ph.D. candidate in Guilarte’s lab and first author of the study.
Dr. Francisco Lopera: (deceased) Identified the “paisa” mutation and was a co-author of the study.Methodology:
Mouse Models: Used genetically engineered mice with familial Alzheimer’s.
Human Tissue: Confirmed findings using brain tissue from individuals in Antioquia, Colombia, who carry the “paisa” mutation (a genetic predisposition to early-onset Alzheimer’s).
Imaging: Advanced imaging software was used to track TSPO levels.
Important Details:
TSPO as a Biomarker: TSPO has been established as a biomarker for neuroinflammation.
Early Detection: Elevated TSPO levels were detected in mice as early as six weeks old (equivalent to 18-20 in humans).
Gender Differences: Female mice (and, mirroring this, Alzheimer’s patients) had higher TSPO levels.
“Paisa” Mutation: This mutation causes symptoms to begin in the 30s-40s, with death typically occurring in the 50s.
Ongoing Research: The team is now studying mice without TSPO to understand its role and expanding the research to include sporadic (late-onset) Alzheimer’s.
Importance:
* understanding TSPO’s function could lead to treatments that delay or halt Alzheimer’s progression. Even a five-year delay could significantly improve patients’ lives and reduce disease prevalence.